Abstract LBA75
Background
Patients (Pts) with locally advanced bladder cancer (BC) have a poor prognosis despite radical surgical therapy. Early data on neoadjuvant immunotherapy in muscle invasive BC is promising, while there are indications of synergistic effects of radiation and immunotherapy. This trial evaluates the feasibility, safety and efficacy of neoadjuvant radio-immunotherapy (RIT) following radical cystectomy (RCX) in patients with locally advanced, muscle invasive BC.
Methods
Patients with locally advanced urothelial BC (cT3/4 cN0/N+ cM0, eligible for RCX, unfit for or refusing neoadjuvant chemotherapy) were included in this prospective, single arm, phase II-trial. Pts were treated with Nivolumab 240mg intravenously every two weeks for 4 cycles, starting one week before radiotherapy of the bladder/pelvis with 50.4 Gy, followed by RCX with standardized pelvic lymphadenectomy. Primary endpoint is the rate of Pts with completed treatment (RIT and RCX) at the end of week 15. Secondary endpoints include overall response rate (ORR), pathological response rates, disease free survival (DFS) and toxicity.
Results
Of 33 treated Pts, 32 (97%) were ≥cT3/4 and 10 (30.3%) were lymph node positive (cN+). For primary endpoint and efficacy analysis, 31 Pts were eligible. Primary endpoint of completed treatment (RIT and RCX) in time at the end of week 15 was reached in 27/31 (87.1%) Pts. Median number of nivolumab cycles was 4. The radiological ORR was 70.9% (CR 16.1%, PR 54.8%, SD 25.8% and PD 3.2%). Pathological response rate was ypT0 38.7% and ≤ ypT1 58.1%. While survival data is immature, DFS rate at 12 months was 90.6%. Any-grade treatment-related AEs (TRAEs) occurred in 54.5 % of all 33 patients. TRAEs were mostly grade 1-2. Most common TRAEs were thyroid and gastrointestinal disorders (each 15.2%) and skin reactions (33.3%). TRAEs led to Nivolumab discontinuation in 8 (25.8%) Pts.
Conclusions
The trial met its primary endpoint. Neoadjuvant radio-immunotherapy followed by radical cystectomy in locally advanced bladder cancer patients is feasible and safe.
Clinical trial identification
NCT03529890, first posted: May 18, 2018.
Editorial acknowledgement
Legal entity responsible for the study
Faculty of Medicine, Technical University of Munich.
Funding
Bristol Myers Squibb.
Disclosure
S.C. Schmid: Financial Interests, Personal, Invited Speaker: Ipsen, Astellas; Financial Interests, Institutional, Funding: Bristol-Myers Squibb; Non-Financial Interests, Personal, Travel expenses: Janssen; Financial Interests, Personal, Travel expenses: Novartis. A.K. Seitz: Financial Interests, Personal, Congress invitation: Bristol Myers Squibb. F. Zengerling: Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Invited Speaker, Travel: Bayer Health; Financial Interests, Personal, Invited Speaker, Advisory Boards: Bristol-Myers Squibb, Novartis, Roche, Sanofi-Aventis; Financial Interests, Personal, Invited Speaker, Advisory Boards, Travel: Ipsen, Pfizer, Merck Healthcare; Financial Interests, Personal, Advisory Board, Travel: Janssen-Cilag; Financial Interests, Personal, Advisory Board: MSD. C. Bolenz: Financial Interests, Personal, Invited Speaker: Janssen-Cilag GmbH, AstraZeneca GmbH, Medac GmbH, Takeda Pharma GmbH, Roche Pharma AG, Ipsen Pharma GmbH; Financial Interests, Personal, Advisory Board: Roche Pharma AG, ERBE Elektromedizin GmbH. J. Gschwend: Financial Interests, Institutional, Sponsor/Funding: Bristol Myers Squibb. M. Retz: Financial Interests, Institutional, Sponsor/Funding: Bristol Myers Squibb. All other authors have declared no conflicts of interest.
Resources from the same session
1449MO - Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
Presenter: Camillo Guglielmo Porta
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1450MO - Efficacy of a tailored approach with nivolumab and nivolumab/ipilimumab as immunotherapeutic boost in metastatic renal cell carcinoma: Final results of TITAN-RCC
Presenter: Marc-Oliver Grimm
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1449MO and 1450MO
Presenter: Kate Young
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Slides
Webcast
1733MO - First results from BladderPath: A randomised trial of MRI versus cystoscopic staging for newly diagnosed bladder cancer
Presenter: Nicholas James
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1734MO - Hypoxic bladder cancers have a poorer outcome following hypofractionated vs conventionally fractionated radiotherapy in the BC2001 and BCON randomised trials
Presenter: Tim Smith
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA75, 1733MO and 1734MO
Presenter: Joaquim Bellmunt
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Slides
Webcast
1310MO - Neoadjuvant platinum-based chemotherapy (NAPC) for metastatic penile squamous cell carcinoma (PSCC): An international, multicenter, real-world study
Presenter: Jad Chahoud
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
512MO - Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: An analysis of the IGCCCG Update database
Presenter: Silke Gillessen
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
513MO - Risk and mortality of testicular cancer in patients with psychiatric or neurodevelopmental disorders
Presenter: Anna Jansson
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1310MO, 512MO and 513MO
Presenter: Aly-Khan Lalani
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Slides
Webcast